August 26, 2010 (FinancialWire) (Go to http://www.financialwire.net/?s=ftrdnwswnd for all of today’s featured news.) — Bioniche Life Sciences, Inc. (TSX: BNC), a Canadian biopharmaceutical firm said it has signed an exclusive global license agreement with the University of Ottawa offering Bioniche the University’s technology for botanical therapeutics and pharmaceutical compounds for treating anxiety and related conditions in animal health, human health and aquaculture.

According to Bioniche, the University of Ottawa researchers and collaborators at the Universidad Nacional in Costa Rica have been studying these botanicals and compounds extensively for nearly 15 years.

The company plans to initially explore developing the technology into animal health products for dogs and horses, where it said the products could help reduce anxiety without the side effects of chemical calming agents.

In the future, Bioniche may also explore the development of human applications for the technology. The licensing agreement includes a commitment to ongoing research at the University of Ottawa.

Canada-based Bioniche Life Sciences is focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide.

The company employs around 200 personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The company develops proprietary cancer therapies supported by revenues from marketed products in human and animal health.

Real-time, streaming research for companies and funds mentioned in FinancialWire(tm) news is available via the Investrend Research Syndicate (at http://investrend.stocksmart.com/ss/html/hpcompany.html). Current valuation analysis research for companies and funds mentioned in FinancialWire(tm) news is available via the Investrend Research Syndicate (at http://www.valuengine.com/rep/searchsrep?pid=42&srchfor=).

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public other companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (at http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation from subject entities, companies, equities, or representatives thereof, for its news, opinions or distributions. Further disclosure is posted at the FinancialWire(tm) website (at http://www.financialwire.net/disclosures.php and http://www.financialwire.net/2010/04/23/safe-harbor/). Additional resources for investors are also accessible via the FinancialWire(tm) website (at http://www.financialwire.net/2010/04/23/investor-resources/). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Copyright © MMX, FinancialWire(tm); All rights reserved.

[hlmsmlh] [biomedphrm] [prtnrshpsphs] [nwdlsldw] [ntrntnlcmpnsbsnss] [cndnexh] [ftrdnwswnd]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.